Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)

NCT03556384 is registered in ClinicalTrials.gov with Adam Burgoyne, MD, PhD as lead sponsor.

NCT NCT03556384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03556384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 2 Efficacy Study of Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Lead sponsor
Adam Burgoyne, MD, PhD
Phase
Phase 2
Overall status
Completed
Start date
September 12, 2018
Completion date
November 19, 2024
Enrollment
23 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, gastrointestinal stromal tumors, gist, sdh